Scott Phillips, M.D. Joins Elorac, Inc. As Senior Vice President, Scientific Affairs

VERNON HILLS, Ill.--(BUSINESS WIRE)--Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced today that Scott B. Phillips, M.D., has joined the Company as Senior Vice President, Scientific Affairs.

Dr. Phillips will be primarily responsible for the continued clinical development of Elorac's robust pipeline of medical dermatology product candidates. He will manage both ongoing clinical projects as well as direct the expansion of clinical research into new development projects. A board-certified dermatologist, Dr. Phillips will also provide clinical support to Elorac's sales and marketing efforts as well as post-marketing activities.

Previously Director of Drug Discovery at GenDerm Corporation and Senior Vice President, Scientific Affairs at Winston Pharmaceuticals, Dr. Phillips has 23 years of experience in the pharmaceutical industry. In addition, he has been Chief of the Clinical Investigations Unit at Harvard Medical School and Clinical Assistant Professor of Dermatology and Medicine at the University of Chicago Pritzker School of Medicine. He received a B.A. in biology from Cornell University and an M.D. from Harvard University.

John Kallal, Ph.D., Elorac's former Vice President, Clinical and Regulatory Affairs, announced his retirement as a full-time employee, but he will remain actively involved in supporting Elorac's clinical programs as a consultant.

"We are excited to add Dr. Phillips to our team at Elorac," said Jeffrey Bernstein, Ph.D., President and Chief Executive Officer. "Scott has an excellent background and a proven track record in navigating new products through the drug regulatory approval process. As a company dedicated to innovations in medical dermatology, we are pleased to add additional depth to our executive team."

About Elorac, Inc.

Elorac, Inc. is a privately owned, specialty pharmaceutical company engaged in the development and commercialization of novel products for dermatology, allergy and oncology. The Company markets dermatological products in the United States through its own dedicated sales force. Elorac has a robust pipeline of products in development, including naloxone lotion for treatment of pruritus accompanying cutaneous T-cell lymphoma, a product that has received orphan drug and fast-track designations from the U.S. Food and Drug Administration, and cidoxepin, the most potent histamine antagonist ever discovered, for chronic urticaria. According to Inc. magazine's 2013 list of fastest-growing private U.S. companies, Elorac ranked 23rd among health-care companies and No. 1 among pharmaceutical companies.

Contacts